Rasmus H @RazBioTech

Founder @ https://t.co/rvCWR16DUM | 🧬 #biotech retail investor | 👀 $OCUL maxi | 🌎 Global citizen | 👋 always happy to connect biotickr.com London, England Joined October 2014

Tweets

2K
Followers

588
Following

273
Likes

2K

ACOSCAP @acoscap18259

3 weeks ago

$OCUL I keep thinking about how $KOD reached $6bb in mkt cap before they card flipped (failed) trial results for #wetamd. Look at you $OCUL at $2.1bb and 5 months-ish to go.

0 2 6 885 0

Rasmus H @RazBioTech

a month ago

Hmm not ideal. I do think $OCUL has a better asset, a better team, and judging by the relative marketcap so does the market.

JNap @JNap5C

a month ago

Hmm not ideal. I do think $OCUL has a better asset, a better team, and judging by the relative marketcap so does the market.

13 3 14 9K 3

0 0 2 654 0

$4.4b annualised - if $OCUL proves itself with Axpaxli this is the benchmark. Not out of question for Axpaxli to change hands for $15b. Stars would need to align - but it’s within the realm of possibilities.

3 4 21 18K 4

Download Image

Rasmus H @RazBioTech

3 months ago

Posted this more than a year ago $OCUL

Rasmus H @RazBioTech

2 years ago

Posted this more than a year ago $OCUL

3 1 9 5K 3

Download Image

0 0 8 2K 2

Rasmus H @RazBioTech

3 months ago

Very interesting regulatory take on $OCUL, $EYPT & $CLSD and their wAMD Phase 3 strategies retinatoday.com/articles/2025-…

2 5 19 14K 13

Rasmus H @RazBioTech

5 months ago

Has a huge position in $MIST. Knew it was a binary, knew it was high risk. Holding on to all of it at a massive unrealised loss. It will get approved. Hopefully in 12 months. Issue (obviously) is financing overhang, and with a $40m mcap there’s no other way than brutal dilution..

0 0 2 442 0

TheForestnottheTrees @richtrades100

5 months ago

$MIST for the bulls. Launch timeline expectation, is quicker than I thought. But I wanted to add, FDA changed the goalposts (after) the NDA was submitted and approved. Milestone may get quicker / kinder treatment because of this. It should in theory be fine. IMO

1 1 12 2K 1

Download Image

Rasmus H @RazBioTech

5 months ago

$MIST this will clearly get to market, question is now what sort of time this review cycle will take. Benchmarks anyone?

1 0 8 1K 0

Rasmus H @RazBioTech

5 months ago

$MIST CRL

0 0 0 472 0

Varro Analytics 🇺🇸 @Varro_Analytics

8 months ago

Made an absurdly intricate spreadsheet to answer question of: "why did this credible person pick this company for the @pawcio2009 #Biopick2025 contest?" Catalysts for 53 co's from prev winners / "100% club" Shared this with smaller group here already docs.google.com/spreadsheets/d…

BioHell Pawcio @pawcio2009

8 months ago

19 5 86 35K 47

22 26 145 101K 121

Download Image

Rasmus H @RazBioTech

9 months ago

$CGON and $TARA (long) both have conference calls on dec 5th

2 5 22 5K 0

Download Gif

Adam Feuerstein ✡️ @adamfeuerstein

10 months ago

BREAKING: Trump picks Johns Hopkins surgeon Makary to run FDA statnews.com/2024/11/22/tru… via @statnews

6 13 99 34K 15

Rasmus H @RazBioTech

10 months ago

Accurate take

Daniel Priestley @DanielPriestley

10 months ago

Accurate take

45 150 2K 82K 14

1 0 0 283 0

Martin Shkreli @MartinShkreli

10 months ago

if you're pro-america, you are pro-pharma. WE make the world's medicines. WE make the world's breakthroughs. pharma isnt perfect, but provides millions of high paying, scientific jobs. very few of the world's amazing drugs would exist without us. pharma hate has to stop. (1/2)

215 144 2K 271K 195

Rasmus H @RazBioTech

10 months ago

Videographer @ChrisWinig might actually move the needle in this election

West Bestern 🛡️ @western_bester

10 months ago

Videographer @ChrisWinig might actually move the needle in this election

169 905 5K 177K 1K

Download Video

1 0 1 253 0

Rasmus H @RazBioTech

11 months ago

I like this timing $mci.v

0 0 0 617 0

Download Image

Rasmus H @RazBioTech

12 months ago

Vabysmo was approved January 2022. In just 2.5 years hits an annual run rate of $4.4b. @JNap5C did great work recently on takeouts in the eye space. 4x of estimated peak is a good guide. $OCUL will 🚀 on good data q4 2025 (my est.)

4 3 17 11K 3

Download Image

Rasmus H @RazBioTech

12 months ago

The language used by $OCUL CEO in a recent webcast suggested that investors shouldn’t expect non-retina assets to be sold off (as I previously deemed likely). He highlighted how important it was to prove that the co could show it knows how to commercialise assets (like dex).